- Home
- CHRS vs FRGE Comparison
CHRS vs FRGE Comparison
Compare CHRS & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FRGE
- Stock Information
- Founded
- CHRS 2010
- FRGE 2014
- Country
- CHRS United States
- FRGE United States
- Employees
- CHRS N/A
- FRGE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FRGE Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- FRGE Technology
- Exchange
- CHRS Nasdaq
- FRGE Nasdaq
- Market Cap
- CHRS 186.0M
- FRGE 354.6M
- IPO Year
- CHRS 2014
- FRGE N/A
- Fundamental
- Price
- CHRS $1.13
- FRGE $44.06
- Analyst Decision
- CHRS Strong Buy
- FRGE Hold
- Analyst Count
- CHRS 4
- FRGE 5
- Target Price
- CHRS $4.51
- FRGE $38.25
- AVG Volume (30 Days)
- CHRS 1.3M
- FRGE 812.2K
- Earning Date
- CHRS 11-06-2025
- FRGE 11-13-2025
- Dividend Yield
- CHRS N/A
- FRGE N/A
- EPS Growth
- CHRS N/A
- FRGE N/A
- EPS
- CHRS 1.34
- FRGE N/A
- Revenue
- CHRS $277,728,000.00
- FRGE $92,884,000.00
- Revenue This Year
- CHRS N/A
- FRGE $32.73
- Revenue Next Year
- CHRS $109.48
- FRGE $21.74
- P/E Ratio
- CHRS $0.84
- FRGE N/A
- Revenue Growth
- CHRS 152.07
- FRGE 16.40
- 52 Week Low
- CHRS $0.71
- FRGE $6.60
- 52 Week High
- CHRS $2.43
- FRGE $44.76
- Technical
- Relative Strength Index (RSI)
- CHRS 29.26
- FRGE 89.42
- Support Level
- CHRS $1.09
- FRGE $44.00
- Resistance Level
- CHRS $1.39
- FRGE $44.76
- Average True Range (ATR)
- CHRS 0.13
- FRGE 1.28
- MACD
- CHRS -0.05
- FRGE 1.59
- Stochastic Oscillator
- CHRS 5.59
- FRGE 97.23
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.